Cintirorgon

CAS No. 2055536-64-4

Cintirorgon( LYC-55716 )

Catalog No. M23919 CAS No. 2055536-64-4

Cintirorgon is a selective, oral agonist of RORγ. Cintirorgon modulates gene expression of RORγ expressing T lymphocyte immune cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 187 In Stock
5MG 143 In Stock
10MG 197 In Stock
25MG 330 In Stock
50MG 479 In Stock
100MG 695 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cintirorgon
  • Note
    Research use only, not for human use.
  • Brief Description
    Cintirorgon is a selective, oral agonist of RORγ. Cintirorgon modulates gene expression of RORγ expressing T lymphocyte immune cells.
  • Description
    Cintirorgon is a selective, oral agonist of RORγ. Cintirorgon modulates gene expression of RORγ expressing T lymphocyte immune cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    LYC-55716
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    ROCK
  • Recptor
    RORγ
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2055536-64-4
  • Formula Weight
    603.53
  • Molecular Formula
    C27H23F6NO6S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:110 mg/mL (182.26 mM)
  • SMILES
    CC(C)(C[C@H]1CN(C2=C(O1)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F)C(=O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017.
molnova catalog
related products
  • BDP5290

    BDP5290 is a potent inhibitor of both ROCK and MRCK(IC50s of 5 nM 50 nM 10 nM and 100 nM for ROCK1 ROCK2 MRCKα and MRCKβ respectively.)

  • BDP9066

    BDP9066 is a potent and selective MRCK inhibitor that inhibits MRCKβ and MRCKα/β and can be used for the prevention and treatment of skin cancer.

  • Narciclasine

    Narciclasine, a natural product, modulates the Rho/Rho-kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity.